CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 20 enrolled
Drug / intervention
losartandrug
Likely dose
losartan 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00879879
NCT00879879N/ACompleted
CompareCT.gov

Treatment of Idiopathic Pulmonary Fibrosis With Losartan: A Pilot Project

University of South Florida·interventional·Posted Apr 13, 2009·Updated Feb 21, 2021

In Brief

A clinical study evaluating losartan for Precancerous Condition. Completed, enrolled 20 participants across 1 site.

Detailed Summary

RATIONALE: Losartan may be effective in treating patients with idiopathic pulmonary fibrosis. PURPOSE: This clinical trial is studying the side effects of losartan and to see how well it works in treating patients with idiopathic pulmonary fibrosis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrecancerous Condition
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 13, 2009
Enrollment StartMar 1, 2009
Primary CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 17.2 years ago

Interventions

losartandrug

50 mg losartan taken daily by mouth in capsule form for 1 year